(Q37799137)

23 August 2017

title

Anaplastic Lymphoma Kinase: role in specific tumours, and development of small molecule inhibitors for cancer therapy (English)

1 reference

23 August 2017

Anaplastic Lymphoma Kinase: Role in specific tumours, and development of small molecule inhibitors for cancer therapy (English)

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.09.001

30 July 2024

author name string

E. Ardini

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20934803

30 July 2024

P. Magnaghi

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20934803

30 July 2024

P. Orsini

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20934803

30 July 2024

A. Galvani

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20934803

30 July 2024

M. Menichincheri

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20934803

30 July 2024

language of work or name

English

0 references

publication date

8 October 2010

1 reference

full work available at URL

23 August 2017

https://api.elsevier.com/content/article/PII:S0304383510004234?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.09.001

https://api.elsevier.com/content/article/PII:S0304383510004234?httpAccept=text/plain

30 July 2024

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.09.001

30 July 2024

1 reference

23 August 2017

volume

299

1 reference

23 August 2017

issue

2

1 reference

23 August 2017

page(s)

81-94

1 reference

Identification of ALK as a major familial neuroblastoma predisposition gene

23 August 2017

cites work

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/citations/10.1038/NATURE07261

EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/citations/10.1158/1078-0432.CCR-08-0168

Oncogenic mutations of ALK kinase in neuroblastoma

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/citations/10.1038/NATURE07399

Development of anaplastic lymphoma kinase (ALK) small-molecule inhibitors for cancer therapy

1

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.09.001

The anaplastic lymphoma kinase in the pathogenesis of cancer

30 July 2024

2

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.09.001

Anaplastic lymphoma kinase: role in cancer pathogenesis and small-molecule inhibitor development for therapy

30 July 2024

3

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.09.001

Inhibition of ALK signaling for cancer therapy

30 July 2024

4

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.09.001

Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma

30 July 2024

5

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.09.001

Molecular characterization of ALK, a receptor tyrosine kinase expressed specifically in the nervous system

30 July 2024

7

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.09.001

ALK, the chromosome 2 gene locus altered by the t(2;5) in non-Hodgkin's lymphoma, encodes a novel neural receptor tyrosine kinase that is highly related to leukocyte tyrosine kinase (LTK)

30 July 2024

8

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.09.001

Unique substrate specificity of anaplastic lymphoma kinase (ALK): development of phosphoacceptor peptides for the assay of ALK activity

30 July 2024

9

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.09.001

Translocations involving anaplastic lymphoma kinase (ALK).

30 July 2024

10

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.09.001

Identification of anaplastic lymphoma kinase as a receptor for the growth factor pleiotrophin

30 July 2024

11

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.09.001

Midkine binds to anaplastic lymphoma kinase (ALK) and acts as a growth factor for different cell types

30 July 2024

12

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.09.001

Differential induction of glioblastoma migration and growth by two forms of pleiotrophin

30 July 2024

13

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.09.001

Characterization of the expression of the ALK receptor tyrosine kinase in mice

30 July 2024

15

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.09.001

Pleiotrophin induces neurite outgrowth and up-regulates growth-associated protein (GAP)-43 mRNA through the ALK/GSK3beta/beta-catenin signaling in developing mouse neurons

30 July 2024

16

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.09.001

Pleiotrophin is a neurotrophic factor for spinal motor neurons.

30 July 2024

17

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.09.001

Behavioral and neurochemical alterations in mice deficient in anaplastic lymphoma kinase suggest therapeutic potential for psychiatric indications

30 July 2024

18

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.09.001

Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants

30 July 2024

19

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.09.001

New neurons in the dentate gyrus are involved in the expression of enhanced long-term memory following environmental enrichment

30 July 2024

20

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.09.001

Expression of ALK1 and p80 in inflammatory myofibroblastic tumor and its mesenchymal mimics: a study of 135 cases

30 July 2024

21

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.09.001

ALK protein expression in rhabdomyosarcomas

30 July 2024

22

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.09.001

Expression of anaplastic lymphoma kinase in soft tissue tumors: an immunohistochemical and molecular study of 249 cases

30 July 2024

23

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.09.001

Expression and functional analysis of the anaplastic lymphoma kinase (ALK) gene in tumor cell lines

30 July 2024

24

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.09.001

Genome-Wide Identification of PAX3-FKHR Binding Sites in Rhabdomyosarcoma Reveals Candidate Target Genes Important for Development and Cancer

30 July 2024

25

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.09.001

Pleiotrophin signaling through anaplastic lymphoma kinase is rate-limiting for glioblastoma growth

30 July 2024

26

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.09.001

Enhanced antitumorigenic effects in glioblastoma on double targeting of pleiotrophin and its receptor ALK.

30 July 2024

27

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.09.001

Ribozyme-targeting reveals the rate-limiting role of pleiotrophin in glioblastoma

30 July 2024

28

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.09.001

30 July 2024

Neuroblastoma

29

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.09.001

Expression of the ALK tyrosine kinase gene in neuroblastoma

30 July 2024

30

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.09.001

Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma

30 July 2024

32

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.09.001

Activating mutations in ALK provide a therapeutic target in neuroblastoma

30 July 2024

34

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.09.001

Mutation-independent anaplastic lymphoma kinase overexpression in poor prognosis neuroblastoma patients

30 July 2024

36

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.09.001

Fusion of ALK to the Ran-binding protein 2 (RANBP2) gene in inflammatory myofibroblastic tumor

30 July 2024

39

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.09.001

Molecular characterization of a new ALK translocation involving moesin (MSN-ALK) in anaplastic large cell lymphoma

30 July 2024

40

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.09.001

Pathobiology of NPM-ALK and variant fusion genes in anaplastic large cell lymphoma and other lymphomas

30 July 2024

44

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.09.001

Morphology in Ki-1(CD30)-positive non-Hodgkin's lymphoma is correlated with clinical features and the presence of a unique chromosomal abnormality, t(2;5)(p23;q35)

30 July 2024

45

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.09.001

Anaplastic large cell lymphomas expressing the novel chimeric protein p80NPM/ALK: a distinct clinicopathologic entity

30 July 2024

46

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.09.001

ALK expression defines a distinct group of T/null lymphomas ("ALK lymphomas") with a wide morphological spectrum.

30 July 2024

48

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.09.001

Role of nucleophosmin in embryonic development and tumorigenesis

30 July 2024

49

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.09.001

Nucleophosmin and human cancer.

30 July 2024

50

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.09.001

Differential effects of X-ALK fusion proteins on proliferation, transformation, and invasion properties of NIH3T3 cells

30 July 2024

51

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.09.001

TPM3-ALK expression induces changes in cytoskeleton organisation and confers higher metastatic capacities than other ALK fusion proteins.

30 July 2024

52

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.09.001

Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target

30 July 2024

53

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.09.001

Inhibition of ALK enzymatic activity in T-cell lymphoma cells induces apoptosis and suppresses proliferation and STAT3 phosphorylation independently of Jak3.

30 July 2024

54

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.09.001

Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell death

30 July 2024

55

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.09.001

The oncogenic fusion protein nucleophosmin-anaplastic lymphoma kinase (NPM-ALK) induces two distinct malignant phenotypes in a murine retroviral transplantation model

30 July 2024

56

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.09.001

Overexpression of NPM–ALK induces different types of malignant lymphomas in IL-9 transgenic mice

30 July 2024

58

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.09.001

Vav-promoter regulated oncogenic fusion protein NPM-ALK in transgenic mice causes B-cell lymphomas with hyperactive Jun kinase

30 July 2024

59

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.09.001

NPM-ALK transgenic mice spontaneously develop T-cell lymphomas and plasma cell tumors.

30 July 2024

60

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.09.001

Ablation of oncogenic ALK is a viable therapeutic approach for anaplastic large-cell lymphomas

30 July 2024

62

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.09.001

Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer

30 July 2024

63

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.09.001

Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer

30 July 2024

64

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.09.001

KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer

30 July 2024

65

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.09.001

Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer.

30 July 2024

66

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.09.001

A mouse model for EML4-ALK-positive lung cancer

30 July 2024

68

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.09.001

EML4-ALK fusion lung cancer: a rare acquired event

30 July 2024

70

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.09.001

ALK gene rearrangements: a new therapeutic target in a molecularly defined subset of non-small cell lung cancer.

30 July 2024

71

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.09.001

EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers

30 July 2024

72

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.09.001

Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK

30 July 2024

73

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.09.001

EML4-ALK rearrangement in non-small cell lung cancer and non-tumor lung tissues

30 July 2024

74

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.09.001

The EML4-ALK transcript but not the fusion protein can be expressed in reactive and neoplastic lymphoid tissues

30 July 2024

75

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.09.001

30 July 2024

EML4-ALK fusion in lung

76

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.09.001

EML4-ALK: honing in on a new target in non-small-cell lung cancer.

30 July 2024

77

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.09.001

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

30 July 2024

78

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.09.001

First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations

30 July 2024

79

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.09.001

ALK1 and p80 expression and chromosomal rearrangements involving 2p23 in inflammatory myofibroblastic tumor.

30 July 2024

81

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.09.001

Fusion of the ALK gene to the clathrin heavy chain gene, CLTC, in inflammatory myofibroblastic tumor

30 July 2024

82

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.09.001

TPM3-ALK and TPM4-ALK oncogenes in inflammatory myofibroblastic tumors

30 July 2024

83

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.09.001

Fusion of the SEC31L1 and ALK genes in an inflammatory myofibroblastic tumor

30 July 2024

84

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.09.001

ALK-positive diffuse large B-cell lymphoma is associated with Clathrin-ALK rearrangements: report of 6 cases

30 July 2024

85

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.09.001

ALK activation by the CLTC-ALK fusion is a recurrent event in large B-cell lymphoma

30 July 2024

86

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.09.001

ALK-positive plasmablastic B-cell lymphoma with expression of the NPM-ALK fusion transcript: report of 2 cases

30 July 2024

87

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.09.001

Identification of squamous cell carcinoma associated proteins by proteomics and loss of beta tropomyosin expression in esophageal cancer

30 July 2024

88

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.09.001

Proteomic profiling of proteins dysregulted in Chinese esophageal squamous cell carcinoma

30 July 2024

89

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.09.001

ALK+ histiocytosis: a novel type of systemic histiocytic proliferative disorder of early infancy

30 July 2024

90

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.09.001

An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms

30 July 2024

92

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.09.001

Non-solid oncogenes in solid tumors: EML4-ALK fusion genes in lung cancer

30 July 2024

93

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.09.001

Therapeutic potential of novel selective-spectrum kinase inhibitors in oncology

30 July 2024

94

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.09.001

The development of imatinib as a therapeutic agent for chronic myeloid leukemia

30 July 2024

95

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.09.001

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

30 July 2024

96

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.09.001

Targeting cancer with small molecule kinase inhibitors

30 July 2024

97

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.09.001

Rational design of inhibitors that bind to inactive kinase conformations

30 July 2024

98

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.09.001

Protein kinase inhibitors: insights into drug design from structure.

30 July 2024

99

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.09.001

Structural Insights into the ATP Binding Pocket of the Anaplastic Lymphoma Kinase by Site-Directed Mutagenesis, Inhibitor Binding Analysis, and Homology Modeling

30 July 2024

100

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.09.001

Anaplastic lymphoma kinase and its signalling molecules as novel targets in lymphoma therapy.

30 July 2024

102

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.09.001

Anaplastic lymphoma kinase as a therapeutic target in anaplastic large cell lymphoma, non-small cell lung cancer and neuroblastoma

30 July 2024

103

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.09.001

Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma

30 July 2024

104

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.09.001

Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors

30 July 2024

105

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.09.001

Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK.

30 July 2024

106

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.09.001

GSK1838705A inhibits the insulin-like growth factor-1 receptor and anaplastic lymphoma kinase and shows antitumor activity in experimental models of human cancers

30 July 2024

107

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.09.001

Optimization of 4,6-bis-anilino-1H-pyrrolo[2,3-d]pyrimidine IGF-1R tyrosine kinase inhibitors towards JNK selectivity

30 July 2024

108

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.09.001

Anaplastic lymphoma kinase activity is essential for the proliferation and survival of anaplastic large-cell lymphoma cells

30 July 2024

109

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.09.001

Synthesis and structure-activity relationships of 1,2,3,4-tetrahydropyrido[2,3-b]pyrazines as potent and selective inhibitors of the anaplastic lymphoma kinase

30 July 2024

110

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.09.001

Design and synthesis of 5-aryl-pyridone-carboxamides as inhibitors of anaplastic lymphoma kinase

30 July 2024

114

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.09.001

Oncogene addiction: setting the stage for molecularly targeted cancer therapy

30 July 2024

120

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.09.001

Factors underlying sensitivity of cancers to small-molecule kinase inhibitors

30 July 2024

121

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.09.001

Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases

30 July 2024

122

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.09.001

Kinase domain mutations in cancer: implications for small molecule drug design strategies

30 July 2024

123

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.09.001

The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP

30 July 2024

124

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.09.001

Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer

30 July 2024

125

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.09.001

ALK mutants in the kinase domain exhibit altered kinase activity and differential sensitivity to small molecule ALK inhibitors

30 July 2024

126

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.09.001

30 July 2024

Identifiers

1 reference

23 August 2017

1 reference